Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
In this study, we aimed to develop a novel gene therapy method for spinocerebellar ataxia type 1 with CRISPR/Cas9 mediated in vivo genome editing using a gene delivery by adeno-associated virus vector. Although we examined SpCas9 and SaCas9 for in vivo knockout, we could not observe the amelioration of an ataxia in a mouse model of spinocerebellar ataxia type 1. Further investigations for higher efficiencies of a gene expression and/or a gene editing are needed.
|